PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34417912-5	2022	The effect of entrectinib on sensitive probe substrates for CYP3A4 (midazolam) and P-glycoprotein (digoxin) were also investigated.	entrectinib	14-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66	
34417912-6	2022	Results Entrectinib is primarily metabolized by CYP3A4.	entrectinib	8-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-54	
34417912-7	2022	In vitro, entrectinib is a CYP3A4/5 inhibitor (IC50 2 muM) and a weak CYP3A4 inducer.	entrectinib	10-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-35	
34417912-7	2022	In vitro, entrectinib is a CYP3A4/5 inhibitor (IC50 2 muM) and a weak CYP3A4 inducer.	entrectinib	10-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76	
34417912-13	2022	Conclusions Entrectinib is a CYP3A4 substrate and is sensitive to the effects of coadministered moderate/strong CYP3A4 inhibitors and strong inducers, and requires dose adjustment.	entrectinib	12-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35	
34417912-13	2022	Conclusions Entrectinib is a CYP3A4 substrate and is sensitive to the effects of coadministered moderate/strong CYP3A4 inhibitors and strong inducers, and requires dose adjustment.	entrectinib	12-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118	
34417912-14	2022	Entrectinib is a weak inhibitor of CYP3A4 and P-glycoprotein and no dose adjustments are required with CYP3A4/P- glycoprotein substrates.Registration Number (Study 2) NCT03330990 (first posted online November 6, 2017) As studies 1 and 3 are phase 1 trials in healthy subjects, they are not required to be registered.	entrectinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	35-41	
34495458-2	2021	Entrectinib is predominantly cleared by cytochrome P450 (CYP) 3A4, and modulation of CYP3A enzyme activity profoundly alters the pharmacokinetics of both entrectinib and its active metabolite M5.	entrectinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-65	
34495458-2	2021	Entrectinib is predominantly cleared by cytochrome P450 (CYP) 3A4, and modulation of CYP3A enzyme activity profoundly alters the pharmacokinetics of both entrectinib and its active metabolite M5.	entrectinib	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-90	
34495458-2	2021	Entrectinib is predominantly cleared by cytochrome P450 (CYP) 3A4, and modulation of CYP3A enzyme activity profoundly alters the pharmacokinetics of both entrectinib and its active metabolite M5.	entrectinib	154-165	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	85-90	
34495458-6	2021	The model was subsequently qualified against clinical data, and the final qualified model used to simulate the effects of moderate to strong CYP3A4 inhibitors and inducers on entrectinib and M5 pharmacokinetics.	entrectinib	175-186	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147	
34495458-8	2021	The model predicted that co-administration of various moderate CYP3A4 inhibitors (verapamil, erythromycin, clarithromycin, fluconazole, and diltiazem) would result in an average increase in entrectinib exposure between 2.2- and 3.1-fold, with corresponding average increases for M5 of approximately 2-fold.	entrectinib	190-201	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69	
34495458-9	2021	Co-administration of moderate CYP3A4 inducers (efavirenz, carbamazepine, phenytoin) was predicted to result in an average decrease in entrectinib exposure between 45 and 79%, with corresponding average decreases for M5 of approximately 50%.	entrectinib	134-145	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36	
34495458-10	2021	CONCLUSIONS: The model simulations were used to derive dosing recommendations for co-administering entrectinib with CYP3A4 inhibitors or inducers.	entrectinib	99-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122